It will become the world’s first company to offer a cross-channel solution for enterprises analyzing data from contact centers, electronic transactions, web, emails, market data, and more. NICE believes this alliance will help them leverage its leadership in financial services contact centers and trading floors, and it expects the deal to contribute $55 to $60 million, non-GAAP revenues in 2008.

As a leader in the financial services market, today NICE solutions captures and analyzes hundreds of millions of voice, web, email and other interactions daily. Its customers include the world’s top banks, brokerages, and thousands of financial institutions worldwide, which seek to improve compliance, enterprise performance, and customer loyalty.

GS notes that positives for the stock include:

The launch of generic Lotrel, a medicine to beat high blood pressure that Teva released on May 18.

The copycat version of Oxycodone, a powerful and addictive opioid used to relieve moderate to terrible pain, is also popular among drug abusers.

ProAir, an inhaler that Teva inherited when buying Ivax Corp. Sales of ProAir have handily beaten expectations. Goldman Sachs notes that ProAir sales benefited “dramatically” from Teva marketing combined with the transition from inhalers that destroy the ozone layer, to environmentally-friendly ones.

On the other hand, competing Tysabri (developed by Biogen Iden) has been reinstated for use by select multiple sclerosis sufferers in Britain, where it competes with Teva Pharmaceuticals’ Copaxone as a therapy for the incurable neuri-degenerative disease. Tysabri had clinical problems when two patients taking their drug, died. However, Tysabri is staging a gradual comeback, mostly based on its sheer efficacy, not to mention the convenience of use. Other MS treatments such as Copaxone are typically administered by daily injection, while Tysabri is given as a monthly infusion.

The FDA, which is known to be slower at approving new drugs than its foreign counterparts, still has not given its approval for the drug to be marketed in the United States. Last week, on the U.S. side, the company heard positive news from the Food and Drug Administration that said they might waive the requirement for the completion of one or two more clinical trials which they had previously required. This is beginning to lead to the company getting more analyst attention, as Maxim Group just initiated coverage with a target price of $10.

EPIX has developed some close ties with some of the powerhouse pharmaceutical giants including GlaxoSmithKline (GSK) Amgen (AMGN), and Bayer Schering Pharma AG , Germany, the world’s market-leading MRI pharmaceutical company. Even though the FDA approval could take six months or longer, these critical alliances should help to insure quick access to the market for Vasovist, when and if it gets the government’s approval for distribution.

On Thursday, for example, when ClickSoftware (CKSW), a small-scale competitor of Oracle (ORCL), announced that their CFO would be presenting at the C.E. Unterberg Emerging Growth Opportunities Conference in New York next month, the stock jumped 3%. A month ago, when it announced that one of Canada’s largest natural gas distributors had successfully gone live with its ClickLocate solution, its stock also popped. Subsequently, the stock settled back down.

There are opportunities where traders can make a profit. This can happen by keeping an eye on the small Israeli stocks for a quick move, going long in anticipation of a news story that need not even be too dramatic, or going short just as the news comes out. Take a look at IsraelNewsletter’s list of Israeli stocks that trade in the U.S. to get some ideas.

Three hundred million dollar Israel-based Ituran, which trades on Nasdaq, sells high-tech tracking, and location systems through locations and partners in the U.S., South America, the Middle East, and the Far East. (Check out its cool video here to see the system in action.)

The Motley Fool community gave the stock a 5-star rating last week, considering it a real value play (they write about the stock right next to a discussion of Benjamin Graham’s, The Intelligent Investor). And Stockerblog flagged the company as one of the few Israeli dividend-payers, and, said it was worth looking into.

Thornburg Core Growth manager, Alex Motola, (whose 3-year batting average has shown more than twice the performance of the benchmark Russell 3000 Growth Index (IWZ)), says that he searches for, “highly sustainable, growing franchises that are selling at reasonable prices and that are not subject to constant technological innovation or price competition.”

According to Kiplingers,

Following last week’s announcement that Elbit Systems (ESLT) will be supplying Lightweight Thermal Imagers to the Canadian and Israeli Armed Forces, as well as other customers worldwide, at a total value of approximately $50 million, the company just had another major military sale. It's selling almost $19 million of ruggedized computers to the U.S. Marines. The sale is going through Talla-Tech, a wholly-owned U.S. subsidiary of Tadiran Communications, which is a wholly-owned subsidiary of Elbit Systems.

The Marines order is for small hand-held computers to provide situational awareness to the forces. It chose the Talla-Tech Rugged Personal Digital Assistant (RPDA-57). The RPDA-57 is based on the Microsoft (MSFT) Windows CE and Microsoft Windows Mobile operating system, Elbit Systems said.